Delving into the Latest Updates on Orphenadrine Citrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Orphenadrine citrate (USP), Norflex

Target

H1 receptor x NMDA receptor

Action

antagonists

Mechanism

H1 receptor antagonists(Histamine H1 receptor antagonists), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesSkin and Musculoskeletal DiseasesOther Diseases

Active Indication-

Inactive Indication

Musculoskeletal Pain

Originator Organization

Bausch Health Cos., Inc.

Active Organization-

Inactive Organization

Bausch Health US LLC

License Organization-

Drug Highest PhaseWithdrawn

First Approval Date

United States (04 Nov 1959),

Musculoskeletal Pain

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC18H23NO

InChIKeyQVYRGXJJSLMXQH-UHFFFAOYSA-N

CAS Registry83-98-7

View All Structures (2)

This study consisted of a randomized controlled trial designed to evaluate a Multimodal Analgesia (MMA) Protocol on patients undergoing Posterior Spinal Fusion. The purpose is to describe the narcotic requirements and usage during the perioperative period of posterior spinal fusion and instrumentation surgery with the implementation of multimodal anesthesia protocol. The study will consist of two parallel arms, with Group 1 receiving our MMA protocol and Group 2 receiving a traditional opioid-based regime. The primary outcome of this study will be the reported Visual Analog Scale (VAS) for pain at 12, 24, and 48 hours after surgery. We considered that our findings could contribute to the fight against the opioid crisis proving alternatives to opioids as feasible alternatives for pain management even in significant surgery, as is posterior spinal fusion with instrumentation.

Start Date05 Apr 2021

Sponsor / Collaborator

University of Puerto Rico

NCT02985671

/ Unknown statusPhase 3

National Clinical Study, Phase III, Multicenter, Randomized, Double-blind, Controlled, Parallel, to Evaluate the Superiority of the Fixed Association (Orfenadrine 35mg, Acetaminophen 325mg, Caffeine 65mg and Diclofenac Sodium 50mg) Compared to the Drug Comparator Voltaren® (Diclofenac Sodium 50mg), in the Treatment of Acute Episode of Mechanical Postural Low Back Pain.

The purpose of this study is to determine whether the fixed combination of orphenadrine, acetaminophen, caffeine and diclofenac sodium is more effective in the treatment of an acute episode of mechanical postural low back pain than Voltaren®. Will be randomized 110 participants of both sexes, aged 18 years or older and less than 65 years of age with an acute episode of mechanical postural low back pain and they will be allocated to one of two treatment groups: Group 1: Fixed combination of orphenadrine, acetaminophen, caffeine and diclofenac sodium; or Group 2: Voltaren®

Start Date01 Jan 2021

Sponsor / Collaborator

Aché Laboratórios Farmacêuticos SA

NCT04509336

/ TerminatedNot ApplicableIIT

Comparison of the Efficacy and Safety of Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients

Muscle cramps are commonly affects patients with cirrhosis. It adversely influences the quality of life of cirrhotic patients. Treatment of muscle cramps still challenging owing to the diversity of the responsible pathophysiological mechanisms.The effectiveness of baclofen and orphenadrine in controlling muscle cramps in cirrhotic patients has been presented in recent randomised controlled clinical trials;however, the comparative efficacy and safety between these two therapeutic options has not been previously investigated.

Start Date20 Aug 2020

Sponsor / Collaborator

Mansoura University

100 Clinical Results associated with Orphenadrine Citrate

Login to view more data

100 Translational Medicine associated with Orphenadrine Citrate

Login to view more data

100 Patents (Medical) associated with Orphenadrine Citrate

Login to view more data

868

Literatures (Medical) associated with Orphenadrine Citrate

01 Apr 2025·Nature Chemical Biology

Carbonic anhydrase inhibition ameliorates tau toxicity via enhanced tau secretion

Article

Author: Keeling, Sophie ; Rubinsztein, David C ; Ureshino, Rodrigo Portes ; Koulousakis, Philippos ; McEwan, William A. ; Lopez, Ana ; McEwan, William A ; Rubinsztein, David C. ; Siddiqi, Farah H ; Siddiqi, Farah H. ; Villeneuve, Julien ; Jeon, Hee-Yeon ; Fleming, Angeleen

AbstractTauopathies are neurodegenerative diseases that manifest with intracellular accumulation and aggregation of tau protein. These include Pick’s disease, progressive supranuclear palsy, corticobasal degeneration and argyrophilic grain disease, where tau is believed to be the primary disease driver, as well as secondary tauopathies, such as Alzheimer’s disease. There is a need to develop effective pharmacological therapies. Here we tested >1,400 clinically approved compounds using transgenic zebrafish tauopathy models. This revealed that carbonic anhydrase (CA) inhibitors protected against tau toxicity. CRISPR experiments confirmed that CA depletion mimicked the effects of these drugs. CA inhibition promoted faster clearance of human tau by promoting lysosomal exocytosis. Importantly, methazolamide, a CA inhibitor used in the clinic, also reduced total and phosphorylated tau levels, increased neuronal survival and ameliorated neurodegeneration in mouse tauopathy models at concentrations similar to those seen in people. These data underscore the feasibility of in vivo drug screens using zebrafish models and suggest serious consideration of CA inhibitors for treating tauopathies.

01 Mar 2025·ELECTROPHORESIS

Analyzing water hyacinth plants from two South African rivers for the detection of seven pharmaceuticals and their metabolites

Article

Author: Mlynek, Franz ; Klampfl, Christian W. ; Himmelsbach, Markus ; Madikizela, Lawrence ; Buchberger, Wolfgang

AbstractWater hyacinth plants (Eichhornia crassipes Mart.) collected from two South African rivers were analyzed in order to investigate their suitability for judging the presence of pharmaceuticals in the water. Thereby, a number of drugs, including amitriptyline, atenolol, citalopram, orphenadrine, lidocaine, telmisartan, and tramadol, could be detected. Particularly for the latter substance, relatively high concentrations (more than 5000 ng g−1 dry plant material) were detected in the water plants. Subsequently, the plant extracts were also screened for drug‐derived transformation products, whereby a series of phase‐one metabolites could be tentatively identified.

01 Mar 2025·Bioresource Technology

High-throughput screening of acetogenic strains for growth and metabolite profiles on readily available biomass

Article

Author: De Winter, Karel ; Vlaeminck, Elodie ; Quataert, Koen ; Palucha, Natálie ; Soetaert, Wim ; Schröder, Eliot

Abundant biomass, including industrial waste streams and second-generation (2G) and third-generation (3G) feedstocks, offers significant potential for sustainable bioconversion, nevertheless challenges such as fermentation inhibitors, CO₂ losses and substrate selectivity of traditional microbial hosts hinder process efficiency. In this study, we address these challenges by exploring acetogenic bacteria as alternative microbial hosts. Using a newly established high-throughput method, acetogens were evaluated for their capacity to hydrolyse and metabolize variety of substrates derived from 2G and 3G feedstocks and industrial waste streams. Our findings demonstrate metabolic versatility of acetogens in converting biomass-derived substrates into a wide array of products while also exhibiting resilience to common fermentation inhibitors. These unique capabilities position acetogens as promising alternatives that could potentially outperform conventional production hosts in achieving 100% biomass valorization while underscoring the need for further research into critical areas, such as the utilization of mixed substrates under industrially relevant conditions.

100 Deals associated with Orphenadrine Citrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00774	Orphenadrine Citrate	M03BC01	DB01173

R&D Status

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


UEGW2018	Not Applicable	Liver Cirrhosis	-	Orphenadrine 100 mg	lohnzjaxpn(umngbnljzi) = few such as dry mouth, drowsiness, and nausea, with no significant difference between their occurrences in the 2 groups jyituccvjb (sxeosildzm )	-	01 Oct 2018
				Placebo
NCT02665286 (CTgov)	Phase 4	Acute low back pain	240	Placebo+Naproxen (Placebo)	itgqrohtld(kzmgswiirf) = gsizymskce mcdpdwcblp (oaumaetzps, wvmocrxpuy - snblldgukj) View more	-	26 Jun 2018
				Naproxen+Orphenadrine (Orphenadrine)	itgqrohtld(kzmgswiirf) = fwgbbrwxmu mcdpdwcblp (oaumaetzps, qofyiljtjj - bcolvrvnim) View more
NCT02665286 (Pubmed \| Ann Emerg Med)	Phase 4	Acute low back pain	240	Naproxen+Placebo	(jreapurtzn) = kqqwsrwstj ywbvrbupgd (nucczhcxvo, 8.9 - 12.9)	Negative	01 Mar 2018
				Naproxen+Orphenadrine	(jreapurtzn) = qwwxbaikra ywbvrbupgd (nucczhcxvo, 7.4 - 11.5)